X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ACTAVIS (US) - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON LTD   ACTAVIS
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
ACTAVIS
Dec-14
BIOCON LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,16217,418-   
Low Rs48310,625-   
Sales per share (Unadj.) Rs194.63,136.6-  
Earnings per share (Unadj.) Rs34.4-391.4-  
Cash flow per share (Unadj.) Rs48.3287.8-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs241.96,803.1-  
Shares outstanding (eoy) m200.00265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.5 94.5%   
Avg P/E ratio x23.9-35.8 -66.7%  
P/CF ratio (eoy) x17.048.7 35.0%  
Price / Book Value ratio x3.42.1 164.9%  
Dividend payout %2.90-   
Avg Mkt Cap Rs m164,4403,728,306 4.4%   
No. of employees `0009.221.6 42.8%   
Total wages/salary Rs m7,4700-   
Avg. sales/employee Rs Th4,213.938,611.5 10.9%   
Avg. wages/employee Rs Th809.00-   
Avg. net profit/employee Rs Th745.2-4,818.3 -15.5%   
INCOME DATA
Net Sales Rs m38,911834,009 4.7%  
Other income Rs m1,571-2,082 -75.5%   
Total revenues Rs m40,482831,927 4.9%   
Gross profit Rs m9,795107,140 9.1%  
Depreciation Rs m2,772180,593 1.5%   
Interest Rs m26026,306 1.0%   
Profit before tax Rs m8,334-101,841 -8.2%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,470 0.0%   
Tax Rs m1,616-5,236 -30.9%   
Profit after tax Rs m6,881-104,076 -6.6%  
Gross profit margin %25.212.8 196.0%  
Effective tax rate %19.45.1 377.2%   
Net profit margin %17.7-12.5 -141.7%  
BALANCE SHEET DATA
Current assets Rs m40,477439,416 9.2%   
Current liabilities Rs m16,783320,463 5.2%   
Net working cap to sales %60.914.3 426.9%  
Current ratio x2.41.4 175.9%  
Inventory Days Days6058 102.7%  
Debtors Days Days8366 125.0%  
Net fixed assets Rs m45,073101,841 44.3%   
Share capital Rs m1,0000-   
"Free" reserves Rs m47,3770-   
Net worth Rs m48,3771,808,934 2.7%   
Long term debt Rs m21,082947,917 2.2%   
Total assets Rs m93,9423,315,181 2.8%  
Interest coverage x33.1-2.9 -1,151.2%   
Debt to equity ratio x0.40.5 83.2%  
Sales to assets ratio x0.40.3 164.6%   
Return on assets %7.6-2.3 -324.0%  
Return on equity %14.2-5.8 -247.2%  
Return on capital %12.6-3.0 -418.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m5,0890-   
CASH FLOW
From Operations Rs m6,400143,216 4.5%  
From Investments Rs m-4,985-342,913 1.5%  
From Financial Activity Rs m-1,775192,667 -0.9%  
Net Cashflow Rs m-473-7,030 6.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare BIOCON LTD With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare BIOCON LTD With: UNICHEM LAB  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  DR. DATSONS LABS  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views On News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 17, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS